Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Nam Nguyen

Dr Nam Nguyen

Nam Nguyen

MSc, PhD


Nam joined the Health Economics Research Centre (HERC) as a researcher in August 2023. His current research focuses on using large databases to investigate variation in antibiotic prescribing decisions for common infections and their association with patient outcomes, in order to determine safe levels of antibiotic prescribing in primary care.

Nam is also investigating the potential for using instrumental variable methods to provide unbiased estimates of the effects of antibiotic prescribing. His research uses large observational databases from both high-income (Clinical Practice Research Datalink - CPRD) and low-income systems to inform localised guidelines and targets for antibiotic use around the world. 

Prior to joining HERC, Nam was based at the Oxford University Clinical Research Unit (OUCRU) in Hanoi, Vietnam, where he completed his PhD focusing on community antimicrobial stewardship in low- and middle-income countries. His PhD project examined community antibiotic use patterns in Vietnamese primary care settings and the feasibility and acceptability of implementing point-of-care testing in private pharmacies to control over-the-counter antibiotic sales. 

Previously, Nam was a university lecturer in pharmacoepidemiology and pharmacoeconomics at the Hanoi University of Pharmacy in Vietnam. He was a pharmacovigilance consultant to the Vietnamese Ministry of Health and a registered pharmacist in Vietnam.

Nam holds a PhD in Life and Health Sciences from the Open University - Oxford University Clinical Research Unit affiliated doctoral programme and an MSc in Medicines Risk-Benefit Assessment from the European Education and Training Programme in Pharmacovigilance and Pharmacoepidemiology (Eu2P).